Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Bowil Biotech is a Polish private biotechnology and biomaterials company focused on industrial-scale production of bacterial biocellulose for medical, cosmetic, and advanced biomaterial applications. The company appears to manufacture ultra-pure biocellulose materials under pharmaceutical GMP standards and has positioned its technology for wound dressings, tissue engineering, regenerative medicine, drug delivery, and biosensor-related uses. Publicly available sources indicate that Bowil acquired bionanocellulose production technology from Lodz University of Technology and commercialized products under the CELMAT brand, including wound-dressing and cosmetic formats. Rather than operating like a clinical-stage drug developer, Bowil looks primarily like a platform and manufacturing business built around biomaterial production and application development.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Bowil Biotech.